High Efficiency of Human Normal Immunoglobulin for Intravenous Administration in a Patient with Kawasaki Syndrome Diagnosed in the Later Stages
https://doi.org/10.15690/vsp.v15i4.1593
Abstract
The article describes a case of late diagnosis of mucocutaneous lymphonodular syndrome (Kawasaki syndrome). At the beginning of the therapy, the child had fever, conjunctivitis, stomatitis, rash, solid swelling of hands and feet, and coronaritis with the development of aneurysms. The article describes the successful use of normal human immunoglobulin for intravenous administration at a dose of 2 g/kg body weight per course in combination with acetylsalicylic acid at the dose of 80 mg/kg per day. After 3 days of treatment, the rash disappeared; limb swelling and symptoms of conjunctivitis significantly reduced; and laboratory parameters of disease activity became normal (erythrocyte sedimentation rate, C-reactive protein concentration). After 3 months, inflammation in the coronary arteries was stopped. After 6 months, a regression of coronary artery aneurysms was recorded. No adverse effects during the immunoglobulin therapy were observed.
About the Authors
Tatyana V. SleptsovaRussian Federation
Ekaterina I. Alekseeva
Russian Federation
Тatyana M. Bzarova
Russian Federation
Rina V. Denisova
Russian Federation
Kseniya B. Isaeva
Russian Federation
Margarita A. Soloshenko
Russian Federation
Оlga L. Lomakina
Russian Federation
References
1. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endo carditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004; 114(6):1708–1733. doi: 10.1542/peds.2004-2182.
2. Baranov AA, Alexeeva EI, Gaedicke G. Paediatric Rheumatology. Atlas. Moscow: Reed Elsevier; 2011. 248 p.
3. JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2008) digest version. Circ J. 2010;74(9):1989–2020. doi: 10.1253/circj. cj-10-74-0903.
4. Cassidy J, Petty R. Texbook of paediatric rheumatology. 6th еd. Elsevier Saunders; 2010. 794 р.
5. Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006;65(7):936–941. doi: 10.1136/ard.2005.046300.
6. Лыскина Г.А., Ширинская О.Г. Слизисто-кожный лимфонодулярный синдром (синдром Кавасаки). Диагностика и лечение. — М.: Видар-М; 2008. — 144 с. [Lyskina GA, Shirinskaya OG. Slizistokozhnyi limfonodulyarnyi sindrom (sindrom Kavasaki). Diagnostika i lechenie. Moscow: Vidar-M; 2008. 144 p. (In Russ).]
7. Oates-Whitehead RM, Baumer JH, Haines L, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2003; (4):CD004000. doi: 10.1002/14651858.CD004000.
8. Weng KP, Hsieh KS, Huang SH, et al. Clinical relevance of the risk factors for coronary artery lesions in Kawasaki disease. Kaohsiung J Med Sci. 2012;28(1):23–29. doi: 10.1016/j.kjms.2011.09.002.
9. Provan D, Nokes TJC, Agrawal S, et al. Clinical guidelines for the use of intravenous immunoglobulin. Department of Health. London; 2007.
10. Eleftheriou D, Levin M, Shingadia D, et al. Management of Kawasaki disease. Arch Dis Child. 2014;99(1):74–83. doi: 10.1136/archdischild-2012-302841.
11. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324(23):1633–1639. doi: 10.1056/NEJM199106063242305.
12. Sakata K, Hamaoka K, Ozawa S, et al. A randomized prospective study on the use of 2 g- IVIG or 1 g-IVIG as therapy for Kawasaki disease. Eur J Pediatr. 2007;166(6):565–571. doi: 10.1007/s00431-006-0280-3.
Review
For citations:
Sleptsova T.V., Alekseeva E.I., Bzarova Т.M., Denisova R.V., Isaeva K.B., Soloshenko M.A., Lomakina О.L. High Efficiency of Human Normal Immunoglobulin for Intravenous Administration in a Patient with Kawasaki Syndrome Diagnosed in the Later Stages. Current Pediatrics. 2016;15(4):401-404. (In Russ.) https://doi.org/10.15690/vsp.v15i4.1593